CYTOSORBENTS CORP (CTSO) Stock Price & Overview

NASDAQ:CTSOUS23283X2062

Current stock price

0.6098 USD
0 (-0.03%)
Last:

The current stock price of CTSO is 0.6098 USD. Today CTSO is down by -0.03%. In the past month the price decreased by -6.17%. In the past year, price decreased by -40.78%.

CTSO Key Statistics

52-Week Range0.4992 - 1.39
Current CTSO stock price positioned within its 52-week range.
1-Month Range0.4992 - 0.75
Current CTSO stock price positioned within its 1-month range.
Market Cap
38.234M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.13
Dividend Yield
N/A

CTSO Stock Performance

Today
-0.03%
1 Week
+0.84%
1 Month
-6.17%
3 Months
-13.11%
Longer-term
6 Months -31.11%
1 Year -40.78%
2 Years -24.69%
3 Years -75.10%
5 Years -93.41%
10 Years -85.88%

CTSO Stock Chart

CYTOSORBENTS CORP / CTSO Daily stock chart

CTSO Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CTSO. When comparing the yearly performance of all stocks, CTSO is a bad performer in the overall market: 89.23% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CTSO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CTSO. Both the profitability and financial health of CTSO have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CTSO Earnings

On March 25, 2026 CTSO reported an EPS of -0.09 and a revenue of 9.23M. The company missed EPS expectations (-76.47% surprise) and missed revenue expectations (-5.56% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported9.234M
EPS Surprise -76.47%
Revenue Surprise -5.56%

CTSO Forecast & Estimates

8 analysts have analysed CTSO and the average price target is 5.36 USD. This implies a price increase of 778.16% is expected in the next year compared to the current price of 0.6098.

For the next year, analysts expect an EPS growth of -33.38% and a revenue growth 8.91% for CTSO


Analysts
Analysts80
Price Target5.36 (778.98%)
EPS Next Y-33.38%
Revenue Next Year8.91%

CTSO Groups

Sector & Classification

CTSO Financial Highlights

Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 65.79% compared to the year before.


Income Statements
Revenue(TTM)37.06M
Net Income(TTM)-10.59M
Industry RankSector Rank
PM (TTM) N/A
ROA -23.14%
ROE -117.35%
Debt/Equity 1.61
Chartmill High Growth Momentum
EPS Q2Q%35.71%
Sales Q2Q%0.92%
EPS 1Y (TTM)65.79%
Revenue 1Y (TTM)4.13%

CTSO Ownership

Ownership
Inst Owners26.27%
Shares62.70M
Float52.90M
Ins Owners9.22%
Short Float %3.82%
Short Ratio21.93

About CTSO

Company Profile

CTSO logo image CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

Company Info

IPO: 2005-06-17

CYTOSORBENTS CORP

305 College Road East

Princeton NEW JERSEY 08852 US

CEO: Phillip P. Chan

Employees: 129

CTSO Company Website

CTSO Investor Relations

Phone: 19733298885

CYTOSORBENTS CORP / CTSO FAQ

What does CTSO do?

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.


What is the stock price of CYTOSORBENTS CORP today?

The current stock price of CTSO is 0.6098 USD. The price decreased by -0.03% in the last trading session.


What is the dividend status of CYTOSORBENTS CORP?

CTSO does not pay a dividend.


What is the ChartMill technical and fundamental rating of CTSO stock?

CTSO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of CTSO stock?

CYTOSORBENTS CORP (CTSO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Would investing in CYTOSORBENTS CORP be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTSO.


Can you provide the ownership details for CTSO stock?

You can find the ownership structure of CYTOSORBENTS CORP (CTSO) on the Ownership tab.